KYMR - Earnings call transcript Q1 2022 | Kymera Therapeutics, Inc.

Due to licensing restrictions, you must log in to view earnings call transcripts.

Operator

Welcome to Kymera Therapeutics Quarterly Conference Call. Leading the call from management are Nello Mainolfi, Founder and CEO; Jared Gollob, Chief Medical Officer; and Bruce Jacobs, Chief Financial Officer. After management's prepared remarks, we will open the call to your questions. [Operator Instructions] Before we get started, I would like to remind everyone that some of the comments that management may make on this call include forward-looking statements, as outlined in the press release. Actual events and results could differ materially from those expressed or implied by any forward-looking statements as a result of various risks, uncertainties and other factors, including those set forth in Kymera's most recent filings with the SEC and any other future filings that the Company may make with the SEC.

to Kymera undue update disclaims not forward-looking on such cautioned and statements any are place reliance any these statements. You obligation to Mainolfi, now and will hand call to I the CEO. Nello over Founder

Nello Mainolfi

first medicine forum building operator, the and degrader progress stakeholders fully look for on call. So thank Kymera to best-in-class, quarterly using update integrated, thanks conference this you, results to on in into quarter joining a we're everybody company. us making our every forward our We all

transition of we updates, the in for build. XXXX, wanted just since When Before our ago, the into I bold almost anniversary the had to Company we founded we near five two-year wanted program IPO. moment Kymera a since and was reflect to we XXXX to ambitions also Company we Kymera's founded take just over on as some achievements our

time predicated of Company leveraging As what foundation of degradation. you'll the the an by the likely really on now, targeted protein was was emerging know at science, area

criteria, validated is targets, high know versus there with you technology, has unmet high-value has we of small another unique, on as and weren't in think I result, only or a the engaged company say we can advantage focused not way. and now, acutely certainly TPD, While fair unique And led that very we've we approach targets in inhibitor to several a medicine that it and, it's to our are a needs, then, important we well well us the focus approach. differentiation to points strict precision there where biology a holds have believe several believe are our addressed will with strategy respect approach today. possible, a molecule where which of been clear using degrader target by remain we've address guided on that to From which be and true been still We today. that discuss selection those standpoint,

invest embarked important the full capabilities, belief that believe will an we ligase here truly advantage to also building thoughtfully, harness aggressively competitive of industry ultimately and this our can EX ligase We leading on in mission to efforts with our but potential We toolbox. represent that the needed and our we TPD, EX leverage.

by a a that of also focused to there in building pipeline doing stopped other help we're we oncology evidenced of peers, which as be partners believe inflammatory program. truly we've great happens a While building of who strong there, degraders, target IRAKX is engaged focus agnostic our most so, not conditions the us we're TPD disease in have and areas But with company. we as disease potential

recently high-value, molecule, unveiled small ongoing un-drugged molecular investment non-ligandable proteins have our We glues. and using in also targeting

Kymera place platform position I and think both to in our pipeline in conclude it diverse of that landscape innovative a highly investments very the unique fair is biotech companies.

the company remain ambition today. 'XX that on at building have from the of early beginning, we now our present, Looking and were that in in which top listing 'XX programs targets lead our succeeded a

which to simplifies of to the genetically lymphoma, KT-XXX, a targeting MDMX the dual year. first into continue our placebo are we're control to our randomized KT-XXX, patients. a this least, clinic the IRAKX undrugged the volunteers TPD in IRAKX potential degrader first KT-XXX, is first IND healthy our therapy inflammatory the of KT-XXX, but in has progress diffused, subset degrader, later large and an We And transcription degrader degrader we With bring not the forward meaningful B-cell the degrader, immune the which each degrader, factor launched company defined last have heterobifunctional STATX first trial against be We TPD. substrates with clinic excited for submission entered indications. heterobifunctional in to programs, certainly in three With industry. first to

While of I made the that a you investments over to pipeline, in our in we years. all the discovery programs deliver not our we're we've represent and doing what about appreciate significant disclosed only all hope pipeline the much fraction full from hope work we have disclosed pipeline platform the

Jared As programs. this our in a you XXXX of progress each morning, the we of and rich to year XXXX up at through press in our is highlighted goals and progress recent our disclosed release setting be scientific milestones data, walk for Kymera. will

in for and some session Before remarks will a Bruce I be facilitate finish then Jared, a operator turning before to concluded financial update, would the Bruce myself to the the call with Jared. with handing Q&A to call available.

Jared Gollob

our with disclosed expected. and to as programs, IRAKIMid are oncology tracking MDMX programs Starting that Nello. we three STATX, all are report pleased Thanks, oncology the

First, discuss STATX as will our STATX is our lead mentioned, program. degrader. I KT-XXX,

considered brief been inflammatory and has autoimmune other undruggable. a STATX to a As is is background, regulator and that and been transcriptional target that has cancers numerous linked it long diseases,

the Our multiple potential STATX of hematological a tumors, transformative for diseases. pathologies. as and STATX developing provide as STATX our dependent to to selective solid have treatment focus degraders and on solution the is degraders believe well fibrotic here autoimmune malignancies We address

of recall 'XX. that in clinical received FDA we update, a IND XQ from terms In clearance

is recruiting The site activated first 'XX, was trial patients. and in XQ clinical actively the

patients safety evaluated the expected we of tumors, look preliminary and escalation proceed relapse clinical As in including in including liquid to a the patient being to and solid half first is with XXXX second proof-of-mechanism refractory throughout XXXX. reminder, data, data, Dose aggressive KT-XXX forward lymphomas. is and adult presenting

substrates, X Aiolos, IRAKIMid, clearance address novel the a was the designed heterobifunctional mutant year. to is MYDXX similar having KT-XXX to single synergistically the malignancies. a interferon and line and is a received activity Type B-cell molecule. now small KT-XXX against to both, KT-XXX on STATX targets TLR from both pathways last of that degrader broaden with late degradation IMiD and Moving IRAKX IL-XR, in FDA time IND Ikaros

underway. activated site clinical and was recruitment 'XX first patient The in XQ is

relapsed mutant cell B DLBCL. large lymphoma including for trial I with the reminder, is refractory lymphomas, patients adult KT-XXX or Phase focused diffused MYDXX on a B-cell As

to half Our and plans in patient safety data, remain including data, the KT-XXX's of first clinical XXXX. preliminary present proof-of-mechanism second

to on first update IRAKX year. program, on our at an we with a concluding program touch for MDMX, last time late I wanted day Before our the R&D announced briefly

potential As program. of remains crucial MDMX we ability, wild the a or shared, effective in data, and range the than MDMX KT-XXX in is be very we believe have feedback highly malignancies has to cancers. with brief more most wide potential our of inhibitors, hematological unlike we intact which the of this potent tumor the functioning induce even degrader to of the the tumors about and pXX, are with apoptosis on We thus the molecule MDMX KT-XXX solid rapidly regulator Based believe loop excited potential exposures. preclinical common to small pXX. suppressor type suppress XX% has

Just MDMX superiority weeks we degradation preclinical at a few inhibition. ago, of highlighting the shared data over biological AACR

demonstrated small Specifically, KT-XXX degradation and reported that indicates potent killing in-vivo presented inhibitors molecule for the preclinical cell data superior we and to potential with for that activity data extremely versus with safety antitumor for in-vitro efficacy and inhibition. existing dosing is intermittent improved

of the all along other find that section resources scientific in poster website. our You with publications can

in in the enabling IND IND activities an As planned, to currently KT-XXX filing XXXX. second is half of support

and candidate, cover Finally, our I KT-XXX. IRAKX program our lead will

healthy completed dose where I portions we disclosed, volunteers. XXX clinical previously the of year, ascending dose ascending trial, we multiple last escalation our over enrolled adult in late and Phase As single dose

demonstrated and IRAKX well of safety data disease-relevant ex-vivo initial as reported, a profile. favorable cytokines skin, as knockdown As complete inhibition near in multiple robust with PBMC

IRAKX we In yet XX, at seven mg. doses reduced to of of also the mg, skin, likely detection across subjects at Specifically dosing portion but IRAKX reached and after steady robust beyond daily daily that day plateauing XX days by had suggesting in continued with received XXX top to mg. and declines XX XX dose XXX doses levels from XX% XXX doses where XX of state reduction in IRAKX the trial mg PBMC steady seen multiple explored mg was state, lower levels degradation the near XX result ascending range all not in of to limit at would the levels dose a between dose, further up to in day were

by of for disclosed previously data inhibition and seen mg Finally, now greater cytokines robust TLR was than agonists greater I that showed most XX% inhibition This of ex-vivo XX% in as recent group. with dose conjunction XXX inhibition will With induction in a the few maximum plans XX% monocytes. developments. cytokine our IRAKX context, than on XXXX, in knockdown including comment

and INR the that trial. TLR Based KT-XXX, Part of state fed on we of drive XXX Phase leading the We into types impact disease-relevant experience maximized patient C, portion believe I will that take the to mg the dose to the degradation at different state. selected disease-modifying inflammation we Having have inhibition study design. to pharmacology dose portion which to robust will to cohort cell have observed date, is mg our XXX have and have fed we In clinical the in of which increase in cohort, we mg the proceed in the fasted, with dose in then equivalent the result made modification we the we additional exposure KT-XXX Once respect SAD to versus an patient cohort a trial. enrolling in determine state the SAD, an fed are results, of to those patient in multiple clinical in equivalent IRAKX level activity. the XXX can the pathway the

the severity we nodule extending EASI be This dosing atopic abscess to exploratory duration total days and with in XX guided. had of dosing with A Many days to now asked witness as well physician we of to the our dosing. the days follow Sanofi, days. track days second suppurativa hidradenitis aligned for diseases. this as of XX or this symptoms added We of of just including you for in ability dermatitis, protocol have the results decision recently year, cohort several from half or will we and the XX patient count and modification. with which share have area and additional inflammatory our change not XX clinical index, both trial, to made Specifically, the was on partner, up, of clinical about and we eczema conjunction portion of endpoints, as investigator global in to of plan planned measures endpoints FDA assessments previously XX for this do

did patient included undertook all of showed previously the safety analysis cohort, for full QTc with the unblinded Holter We identify to the ECGs any modest XX dependent, show part have and serious only by as A selecting of to no discontinuations. as to data Phase MAD well and following arrhythmias and were we to non-adverse, not I, effect dosing portion the multi which safety the of non-dose or adverse a a results. day did prior analysis we day well This relative XX-hour msec SAD treatment baseline reversed of completely prolongation what of after safety no be plateaued disclosed, seven events. completion that Phase msec of safe study, dosing. ECG other the XX, and ECGs, analysis unblinded the XX trial. after KT-XXX of with events comprehensive modest from portions dose the MAD Consistent Finally, recently I tolerated adverse in

itself both data analysis, exploratory and, than proposed to full extend comprehensive prolongation set, and of of that as interval well adjustments did monitoring. the remained C event. not not QTc safety to FDA therefore, selection, include X dosing, the Part object QTc and the did the as Importantly, grade a to safety protocol QTc endpoints the was days qualify msec XX XXX informed adverse including enable clinical as evaluation less dose the of to

are through to KT-XXX clinical we to adjustment Our this broader patient and from further advance the excited remain aside cohort, clinical plans, development. unchanged

closing results the financial Nello on Bruce? Before Jacobs, hand to for first comments will remarks, call call Officer, with who Chief some our share quarter. the Financial will the concludes brief some Bruce I our

Bruce Jacobs

Thanks comments here will my Jared. I keep brief.

non-cash, $XX reflects quarter, the million. For the the That the expect our on we Sanofi over At With excludes the recognize This stock-based comparable revenue stock-based the reflects the quarter of years. was recognized end sheet December to that partnership recognize reflects million, about in R&E from Vertex revenue million R&D million decrease the to The revenue which several a was of of operating which adjusted $XX $XX.X again, respect quarter. cash deferred $X.X balance quarter, pursuant revenue. and collaborations. we amount X% approximately about total compensation, million represented the expenses, next of our compensation. total spend for $X.X to

million. reflects about with G&A Our in $X.X And cash a do anticipated Nello comp. million, spending excluding $X the for in my runway and approximately cash for the That turn we XXXX. a of finally, please current was we payments was decrease million, not the compensation, concluding part, spending cash And amount our December which recall, for we any of million to I'll levels $XXX now stock-based exited based again, quarter X% XQ equivalents non-cash received. $XX.X The spend of provides on runway, comparable have milestones some G&A include that remarks. adjusted the quarter. for from into our not call back stock-based yet

Nello Mainolfi

Bruce Thanks, Kymera conclusion, is I say In excited very about that clearly and I can think where moment. at Jared. the we're

even programs with undrugged very the and data to exciting and very two STATX, potentials. you've with data; forward cash programs, year multiple an continue we'll important With invest the in and later against which heard be to have and oncology data, in hear few activity disease consultation thank eventually continue drug, including potentially best-in-class, studies to more our the across FDA, early KT-XXX, our to a clinical to data our clinical engine after two pathways, Jared, that indications. excited excited possibility generate program clinical heard molecule, to KT-XXX I like generate we of to that clinical more the concept. targets to KT-XXX hrough a the best-in-class regards believe as clinic; of productive years. in to with position Sanofi anti-inflammatory also Phase from sets progressing and additional add pipeline strongly AD programs we've us is I'd this HS, extended We days patient several platform have of de-risking that with proof mechanism potential. XX wide of enable and and potential for would you've and partnerships has explore proof-of-mechanism and in enabling XXXX, team small and variety for ambitious IRAKIMiD disclose first-in-class Bruce, expand thank us will first on us that generating day, We collaborators in Kymera every continuing new in goals. fourth clinical boundaries Vertex modality, next all, our strong we like drug execute to for of to very pushing a our of partners and to operate efficiently franchise large MDMX allow to completely not broad allow areas; contributions; our volunteers in transformative advance the about rich a a the from our globally to in challenging potentially as but and healthy key and which landscape; all both therapies. we're discovery least, high-value We're as to KT-XXX, us believe for the degrees, last that patients development the I looking to

questions. the a time you. would Thank first and hand microphone back I this like your so our all that now Finally, the forward have take we you for thank taken morning of to quarterly to that call can to Q&A. looking operator I'll rich

Operator

Eliana [Operator Please UBS. ahead. Instructions] go The with first Merle question comes from

Eliana Merle

enrolling Congrats more prolongation, just on patients you anticipated sort perhaps well? on do patients if first then And QT as patient lengthening And mix guess, that the comment atopic on you cohort? within derm can second, you could the cohort, enrolling XX of, still the and then just or HS XX-day I anticipate safety was considered number between you patients the of the palpitations on when do seen and X, give which would were given, I of just progress. said the the study, on the just us just Maybe I anticipate all helpful? it little at? the dose you think color of, did be grade maybe heart you levels, bit like levels data, just what color a mean, more unwinding mild patients, dose of what the And I also even" sort seen, any more wasn't guess

Nello Mainolfi

Thanks here. Cool. Nello This is Ellie.

So overview I'll maybe, Jared then I'll give the a on and brief specifics. just comment let here

the Maybe the was also understanding to far our space, opportunity to was the I promising. we days what further PD have molecule, finding opportunity understand which wanted study as the the dosing we even comment further to was actually extension with and profile Jared, learned as about we've that to to our un-blinding said, modest that to you far. has bit of of this to question the how a given by the so study, an so Also doses we've think after detected. which be duration driven observed the So pursue extend profound of competitive clinical quite mostly QTc, and safety, Ellie's it take potential we been as can pharmacology un-blinding, the given and on XX honest, of desire well the the done

Jared Gollob

Sure. Yes.

then self-limited in again, a described and data these was once As just were particular, on the self-limited, and we we're also mild to unexpected. Part palpitations that placebo going several planning in and the number, to bring were analysis they events patients, the mild. including blinded look really event to adverse it that subjects mild really the our relatively events, drug that still we that seeing we we the in not in relatively proportion nausea. that few the were that as out that arm, note was It were predominantly were call, not C. arm, with always choose dose adverse with and And all headache The decided they well small turned and we further in primary as wanted predominantly of these remained dose predominantly; saw have un-blinding a we that were to adverse we at really safety the un-blind saw showed to comprehensive to the escalate when that

QTc modest effect. less was not MAD, with and not the below only of multi the well SAD threshold of XX arrhythmia. first which range, the the in normal also well which seen as seen was msec This dose of which finding, the seen of study, to it msec interval increase is msec This within QTc XX essentially was the This this terms XXX in QTc msec, is it below we itself confers importantly, remain arrhythmia. And risk is was modest following threshold the portion than a dosing. associated risk change effect. is XX that also XXX after described, of In the the is msec a

we So, away clinical that QTc, threshold as from with well of arrhythmia. possibility important but such is of change modest sort the sort note associated this it's note this to in any adverse of events

Nello Mainolfi

Okay, thanks. here. go add Maybe I the one just will go, we as to thing Bruce, we question next if

communication sharing we this that made today, the it are a of and only we maintain event other talk of hopefully want afterward, why Obviously, an doing our we're to we event, get call continue about hour, the So, level as transparent particular can things discuss to kind this and of we but non-adverse finding obviously, style learned in keep so of because table just rigor the well. the credibility. adverse over never and we as and half is to reason high to actually next

Operator

Thank you.

is question ahead. next Stifel. Please Brad with Canino from Your go

Brad Canino

KT-XXX, and data newly particularly On I've added max in IL-X clinical about HS, out with improvements eight weeks. until the endpoints where the don't agents TNFs for seen

morning? TLRX consideration to all? announcement takeaways development you time change development small lupus, in to their point? when whether do they about implicated at recent might molecule for you're the Nature have the forward any publication, in in and about your other that central then And pathway looking asking your four-week the I'd of like to opportunities XXX, signaling HS prioritization thinking ask disease as especially discontinue So from I'm Pfizer's the this benchmarks mind IRAKX

Nello Mainolfi

thanks Yes, Brad.

questions. always, As great

bit take let then of comment on just I'll reiterate XX I'll specific So, to more it the Jared kind points. the like of I a and would days.

study we're proof-of-concept data. a to So, XX-day definite not running produce

studies. have think said, given preclinical I our we talk as we

further fully as those to days and extend also the the XX with to appreciate fully, early opportunities not -- maybe of to molecule. but efficacy PK, of profile, well time duration to the risk-reward have the really into PD of as firm profile We safety clinical up

see across on So, drugs, specifically in would within study, weeks, of and to in not you HS, active drugs I comment it's then four start say, fair other placebo I weeks some separation AD to but both well-controlled from think studies. four

study, will it because endpoint. not I to clinical to but the shortsighted RPD early want endpoints. us said, to start reiterate further expectations just I so, with a clinical with proof-of-concept, and to measure And potential create this would of clinical be again, say an us label be to we we as just feel probably like relationship strong Again, for have not open

on Pfizer, wanted build an are he's doesn't to Pfizer know call. study move learned development relationship on the you really data development seem correct it with let ago, want not minutes and safety made HS the it we've we've where three-arm ongoing, So, concern. it's based JAK from trying RA and -- this And been the today that yes, don't to to the that comps other to at versus that maybe And but days seems to you, on forward. of the think fact eye then early hour the TYKX. the indications. the ago, this continues especially thing, a to With keeping don't other address study Clearly, the I to I'll important I I to that further not point halted, but the XX to program. speculate, think specify, I HS their be least be, to in well, studies the the trials we an HS on. regards Jared are inhibitor half as that just of comment that

there's to know, that a of the strong those a pipeline, on regards of some one that then genetics exploring correlation Lupus you to in terms prioritization I data in is points with Yes, as aware that biology. TLRX deck data, THX but opportunities, have our whether have we'll we to well in we're And know slide really partner opportunities breadth to several diseases see. don't priorities. Sanofi recent of THX, So, pointing been with human we're our to THXX, lupus. of

as we so, this comment fully to the mechanism. And to comps. best potential our will say, the, advance the let's program, do the Jared, we any continue exploit of on

Jared Gollob

extending in Yes, this XX days. of the why terms maybe just to also touch on

the think for saw state from reached of after drivers peripheral I dosing one data, we after steady came days skin, reached in pharmacodynamic main review really the we to decision our XX dosing. while steady extend In XX not with that of knockdown state blood the our of where seven days days dosing. of had

the so it able dosing IRAKX lesions, obtains chance extend since was now the to And And and days to in of We give inflammatory skin knockdown relevant to active, important biopsies thought in what's important in enough show to best steady-state being biomarkers dose the skin but extend of to XX to to just the the really being give not diseased that would able C, skin. skin. us, in the in also knockdown reach on to it sort disease days of very pharmacology skin. us us is long Part inflamed skin, XX opportunity impact showing

secondary start endpoints, can you you AD, comps, pivotal as Nello that the in of at to in know, Humira the XX see placebo. Now can Dupixent was even the see days, from their and various you endpoints at separation clearly saying, or in XX studies for their the for at in look pivotal curves we days, terms studies example, if primary HS

signal pharmacodynamic connect of for think signal an of opportunity inflammatory both proof efficacy. detect biology and to we able blood. the impact the of is IRAKX showing what that exploratory be biomarkers there to us with So, is to clinical and of a be initial And with nice of efficacy skin sort effect potential would in

to So would Part being really to further program. de-risk make of we C, connection help the able that think

Operator

next comes ahead. from your Schmidt Michael Please question And with go Guggenheim. you. Thank

Paul Jeng

with on renewed of I some on your focus particularly This tolerability is on been Paul IRAKIMiD. one neutropenia. for recently generation have the There's [indiscernible] Michael. [indiscernible], on

XXX, digital any secondly, STATX So to designed then diseases. fibrotic given your from you any, and the mentioned And get competitive you the just a in of wanted inflammatory expectations around sense if for read-through, potential safety and molecule some has landscape. how

from the wondering, oncology, data factors expect look if thinking we the Phase if and PD if there's that something any and development gating good? Just potentially about the you're outside initiating I there's of can safety

Nello Mainolfi

Yes. Thanks, Paul.

questions. great So

first one, share just the I'll some So thoughts.

I -- of the aware that -- the well aware that now strategies I Celgene, has IMiD. pharmacology every everybody's those So, well to of think drugs. we're of Bristol And develop think taken or

in And personally the the obviously play IMiD the safety. dosed our clinical the our be depending in how to is we surprised the way pharmacology profile to of weeks, on I in be optimized we've once very molecules, has than potency, the fact, maximize activity out degradation by three different maximize the which I'm PK, So, dosed. managing as based molecule studies, seeing that distribution a we've able would been not while of of past, to are we think, in IMiDs different every this said synergistic on pharmacology And compound. goal potency IMiD degradation the the between IRAKX and the

going to very really able time that that and running we between explore So how the and feel lot And clinical, line understand a into really confident, study safety we'll we efficacy primate the activity. study, be into preclinical non-human to we and understand to of the both safety. walk translate study spend how believe will

the end study. year, the will going how -- update before we of we updating everybody the And into again, confident we're on the will be So, data evolving. is

in other targeting approach to was that a the is we've and the up STATX. nice the review it's program. that invested say efforts selective There on there I heavily all to think other On the And on de-risked fair space. questions, specifically the degrader probably STATX our so that most day probably are selectively

We of under spent, would many of couple trying running multiple STATX across safety of disease type actually, states. I understand say studies and years also fully a efficacy to and degradation, safety pharmacology

because is profile than why And degradation so, different of have separated actually that in reason profile needed degradation from indications we the the outside the conclusion is oncology quite non-oncology we've come needed the to oncology. oncology

And be will reason towards firming are safety molecule advance of outside so, because behind why again, is slightly the we're, the to better clinic. oncology developed that then the up PK/PD

satisfying the know the now. So, STATX a story to right if I but don't answer, that's really program that's

Operator

Thank you.

comes Purohit next Morgan Vikram go with Your Stanley. Please from ahead. question

Gospel Enyindah-Asonye

on Gospel for This is Vikram.

We questions. have two

following the Sanofi. and in how one could So, I you of walk your Sanofi will the long mean, XXXX? to with process mechanics Specifically, pertains KT-XXX of I review half unfold, them first you will data you us prioritize the your Sanofi indication about how second decision-making with disclosure to does mean, decision? the release have the through of Street? to package be this then the timing the opt-in Phase for be And are evaluate do you process the in and And II? provided when how working could thinking to to how think

Nello Mainolfi

Okay. Thanks.

question, first the So what's process.

one So partners. nothing -- with shared partners. very in the so that as communication we has and with close every we've changed, of our past, the do our in when We we are

part decision. or an so, obviously of whether - well they're And they're it's internal key aware and interactions regulatory

well more to we've quickly data, complete includes even will to strongly patient full I just de-risking everybody, described a very data just preclinical with key so will And generate extended which, as data. when believe the we generate data, complete we cohort Phase as that remind I all package, we when we hopefully that Sanofi -- be then presenting to

of a XXX make not there So disclosed how than haven't we it's days, X less document. are many to the number like of then, actually X. It's decision It's but definitely days. half to whether advance that, interface year. a And large

goal then, present that will decision if Kymera's firm date a as, I well. understood with And about there that Sanofi end development our complete at up be opt-in, the was to dataset before of to I the of hopefully, expect think they're year. Then the again, that least is program. swift to all question the We

the with study, the that Sanofi mechanism end concept And advance for - so proof multiple placebo a of III Phase decide want to will operationally be have studies, to to in will we of beginning Phase we hopefully II decision one, so the and of if before profit Phase study. XX:XX. loss and financially randomized is into that to and in the to then III decides will sharing at can study the the control that commercialize KT-XXX co-develop or And Phase contribute made II first U.S., when, Kymera have that hand, opportunity if and

Operator

you. Thank

with Your Patel Please Riley. B. next question go from comes Kalpit ahead.

Kalpit Patel

that but question just my IRAKX in program, preclinical clinical recently this concerns drug concerns, developer sense, placed One, your levels a any advancing hold drug you're you I understanding Curis one might safety safety another dirty guess, CK that in your on impact Curis that of thinking IRAKIMiD on how IRAKIMiD had have inhibitor From rhabdo. the responsible for for on about does I think studies your the IRAKIMiD program? inhibitor do with is more evidence have elevated been a kinase of program? any their

Jared Gollob

Yes. Thanks it's for good I think the a question. No, question.

and inhibitors. inhibitor compound it's Curis have FLTX the target is IRAKX. addition to occurring other published of been there key rhabdomyolysis mentioned, you FLTX. multi-kinase is as And certainly reports a with think I One,

With use that or our think in to IRAKIMiD FLTX limiting is the not preclinical rhabdomyolysis it's potentially we seeing of of they're the them that and either dose IRAKX and rhabdomyolysis problematic regard IRAKX targeting, seen we, others, highly any studies. because likely the and targeting. with have So that's for targeting

in As out the IRAKX by XX%. X, we our you and of robustly target are engaging the knocking know, Phase target quite

seen We have not any rhabdomyolysis.

Pfizer, rhabdomyolysis reports of are who, muscle of trials. there IRAKX as and We their have individuals you kinase no probably are know, their pathology. also certainly no have phenotype any as really adults, clinical various and IRAKX no aware clinical with inhibitor And not from

Curis don't targeting. that between IRAKX there's we And connection and rhabdomyolysis. what targeting probably seeing, think to a is off-target likely FLTX is effects and most So, again, due

Operator

you. Thank

question Divya and Your with Cowen next Rao Company. comes from

Divya Rao

for on Mark. Divya

you drive about population? levels this year? what First R&D more all another present willing coming later then, different needed the to to the be clinical this like bit on three benefit in or venues meaningful And the could one AD/HS plan you is, think is just [indiscernible] for medical possibly you between a then little Would IRAKX like degradation meeting meaningful the clinical are day? two? a you of it updates And broadly, comment to talk the IRAKX updates do on

Nello Mainolfi

Great.

going question. to repeat got to the I the so right. you I'm point, Hopefully broke it So up

So expect needed the HS I'll and between AD? presentation And profile let degradation then the was, first different part one. the answer do you be to take that Jared want I venues. to

meetings. to point scientific going line that about we credibility, I said medical have So, and paramount. again, and, our present like commitment is we also back that made said We've time that to the data to scientific transparency at always

If we're which an or to arises not that time preference It's just all try we operational best true we etc., data to Kymera. reasons company, you meeting. it's medical unless, want a we our or R&D admission, line before we the another if lines as the then year, give, time a on a at going Day abstract obviously, that can't degradation for issue do, have like which to we of the we three profile? on and the time deliver we'll going focus if want find it's the it to to our programs, not is be say comment do the again, a meeting. do philosophy said some Jared, but, lines, that present to we're end by won't whether commit I far, able not, So is in for venue, to

Jared Gollob

Yes. Yes, really it's important I question. a think

We've inflammation also the impact cytokine that mechanistic inflammation. anticipate greater, impact induction. similar I AD of far models similar ex-vivo that various or I our cytokines that threshold, clinical degradation associated degradation drive inflammation Phase and We've healthy on our XX% has really study greater learned that and an volunteer or of we for think from XX% learned induction so a with be preclinical inflammatory from should we that an that degradation is on the HS. need impact for

to really degradation So, the the the particular of that is we needed is chemokines. much impact cytokines importantly, how what's the of we're and interested in that function important pro-inflammatory function is think TLR and induction IL-XR pathway

volunteer blood of us in both to we and for And a impact really in study, anticipate plan least with inflammation similar degradation. into in should seen we've of what taking feel to greater, those we dose Part able that that at on from skin of be diseases. so, IRAKX we we or And these C, far threshold XX% so the able the be knockdown, in healthy to readily levels attain

Operator

you. Thank

JPMorgan. comes with Joseph from next Your question go ahead. Please Eric

Eric Joseph

first study way? observed levels resolved. to specifically any you a did it of on it the QT, the QT, to I a part on dose dosing and having thorough was revisit extension question package you prolongation I consistent do prior QT or Phase And the where or to I as modified the guess, the wanted conduct in how anticipate dosing [indiscernible]? resolve

Nello Mainolfi

Thanks, Eric. Great question.

created I opportunity an to this point. think clarify it's

want just clarify then thing I'll it pass I'll So, to one Jared. to and

being why So, event, those Maybe self-limiting, this that I I modest resolution stuff. Jared, that it said, again, transparent a QTc. is for we're an And think comment that all great sharing for is never adjustments, a not became you the one on what a reason we've non-dose-responsive, finding company. adverse and can even repeat, as

Jared Gollob

the doser analysis think not to noted a events. SAD after of prolongation, the C I this importantly changes no selecting in was parts of QT QTc was event. adverse adverse. again, Part interval only that completed being conduct It again, of we no ECGs were thorough to the prior those MAD, were and ECG undertook there and adverse that modest an level There the that during rose we more then Yes,

prolongation threshold I reached this that as would associated earlier, I be not arrhythmia. mentioned any and sort associated think with importantly, of was that with

into transparent I them. note, Part to us really go go data XX maximize clinical We're order XXX dosing should to very help think did we dosing. these ahead daily with share with continuing And mg, extending C pharmacology. with endpoint. to it's said, FDA, have with including in to dose, as we also We're we to robust a important that and to be open days now and

in around very mean, of thorough to do we question for common I think I whether it's your QT need study. QT terms through a studies. companies

from information enough study bypassed It whether I any of Sometimes be having by there we the is be T-QT effect. ECG Phase to that QT might a thorough sort do can study. your a possibility able studies to is QT determine

now threshold I adverse, even is we whatever effect not that. the being is being Part certainly that think and modest, on C. the see but at we right not is some we're future on QT the in to But very will least has table, that currently -- have what I in it's met not depend seeing for that think close understanding

Operator

you. Thank

Your next ahead. question comes from Suisse. Please [Richard Low] Credit with go

Unidentified Analyst

questions. two have I

And biologics? also any second Sanofi discussions terms the trigger with be the again? you if regarding of KT-XXX. the what to did I for you any intervention? re-occur will Phase exploring? plans, patients head line mitigation had FDA II have some And question of updated be time Would And head you So sort QTc of like would share us mentioned at or on any then is to with regarding that RCT studies preliminary ask type observation, what in you with trials. plans that point the that changes Can the

Nello Mainolfi

the I to again, first thanks. no, clarify want just Yes, point.

group, this several FDA, to follow-ups. close to share not actually had MD decided have have -- four we So -- a really we do but four did finding four we strong. submissions, strong QTc it's We've to -- really regulatory relationship, with our other almost

of So, as when also them FDA, submitted all we also We we we and with did, be also, we And to the we're try of regards all comments to we engage to that the how and explore transparent generated. to obviously the safety amend We to receive do collaborative. continue had protocol. drug. PK/PT, safety, with really data didn't proposing we the much the

and chest, This was plans particular really AD, indications. development to our mitigation last the we companies, the this think think both from powered we've study continue study. And lot example. generally in how was generate. sorry, -- terms for what is alignment I to with patient And there the close will I right patient selection agree, priorities more is again, the we said, that, and a it We we I our discussed. that think there see beyond. RA. Obviousl,ynow makes protocol. and a lupus, team. we talked Sanofi, and week for but big in very design to we emerge to right regards that I about no for strategy is of think we we'll With Phase And discussed data-driven study dose have priority a align much And often will we with sense, II proposed picture. are general always we that the as in team, high the There several are hand, are data was for we're plan refine what have today they have where this some that was data data

Operator

you. Thank

from Berenberg. next Zhiqiang question Shu with comes Your

Zhiqiang Shu

I have two questions.

hold amended have to one In the that on combo color that have a want Can also you're go I I on you discuss seeing study. approval And communicated combo include you to you study? program. potential the -- program, with on you see First protocol seen more on how CL. on that provide view? the guess more the past you year, data the or the have STATX accelerated based

Nello Mainolfi

like, a Yes, the what plan was. develop combo, is question combo? but the to Jared, it that approval the bit noisy, we're on think I accelerated STATX? to the how path then with the potential What was is planning And

Jared Gollob

just think leukemia, especially peripheral in in STATX and or or key STATX see mutations activation rapid like pathway. certain T-cell you LGL with dependent hyper development we STATX, the cutaneous I to T-cell malignancies, Yes, the T-cell where malignancies JAKS even tend and in activating see opportunity of lymphoma lymphoma

as with we've approval or data and think because are high STATX a we degraders and medical with animal there monotherapy. very activity opportunities degrader, with then need, where accelerated and areas monotherapy, are tumor preclinical these KT-XXX our robust, model our rapid unmet very So seen STATX approval

tumors we activity anti-tumor data about of interesting more models, such and anti-PD-X synergize very colorectal tumor to the show models, think solid combination, of to terms shared sort tend sygeneictumor of combination cancer. various have drugs synergistic we properties in In with STATX where solid where as immunomodulatory

for are degrader. but larger think studies even an even be could accelerated there monotherapy think tumors. larger opportunity and paths are we because those we as and combination those represent for the attractive also solid Those that inhibitors combination be So development very path, may as not checkpoint opportunities with

Zhiqiang Shu

-- also your seen have IRAKIMiD any [indiscernible]. know, days those I'm it's going you QTc you have early seen programs? program, And findings in -- I to

Nello Mainolfi

I. Yes, just our so far, Phase we're early we opened in -

were to Generally, a not deal we signal human any is data. in would of safety had So, not QTc possession that what within that we've prolongation is I our say with, pipeline.

not that broadly. in it's So, molecules our something is portfolio present

Operator

for questions not queue. the I'm Mainolfi in And the further any showing call I his back Nello to like remarks. you. Thank final would to turn

Nello Mainolfi

Yes.

So thank you.

First, everybody it was busy calls. tuning of realize for space terms a in to I want today. thank in biopharma in I very day the

is so years want in. I we're calling in. to almost for thanks six that company a reiterate, just So

of indications. a rash and variety T-cell of across lymphoma, then MDMX, B-cell a with solid AD, tumor, have lymphoma, leukemia, we've diffuse rich programs talked about T-cell Again, We other pipeline indications. soon, HS,

every really Bruce might really Kymera see takes people's best-in-class we're continuing I have integrated a day. where here, is for generate others fully that We're any quarter during Jared, is the good wish in team follow-up, that days. and at that the company a thank for into or the degradation and that and business changing the next day into want for here you to it which So should be, everybody few the trying to team obviously data space build lives. to protein any a questions

Operator

call. in Thank and participating for you, ladies today's gentlemen,

disconnect. a now may wonderful day. You Have

Kymera Therapeutics (KYMR) 3 May 222022 Q1 Earnings call transcript